02.14.12
Ockham has completed the acquisition of Nexus Oncology. The combined company will operate under the name Ockham and will be led by James V. Baker, Ockham’s chief executive officer, and a joint management team. Nexus Oncology will run as a separate unit under Clare Wareing, founder of Nexus. She will serve as chief scientific officer.
With the addition of Nexus, Ockham now has approximately 300 employees across 12 countries. The merger enhances Ockham’s global scale, as well as oncology-specific therapeutic expertise to deliver oncology trials of all sizes across the drug development spectrum.
Mr. Baker said, “Nexus is a first-class organization that has a history of providing excellent service in oncology clinical trials throughout the world. The experience of the Nexus clinical team and their leadership will help the newly enlarged company to expand our services and be a force in getting life-saving oncologic drugs to market more efficiently. Ockham is excited to have Nexus as part of our family as we move forward in our quest to be the number one global oncology and specialty services CRO in the world.”
Ms. Wareing added, “We are absolutely delighted to be part of this new organization. This transaction enables us to realize a long-held ambition of being a global full-service oncology CRO with a larger geographic footprint and a wider and deeper service offering.”
With the addition of Nexus, Ockham now has approximately 300 employees across 12 countries. The merger enhances Ockham’s global scale, as well as oncology-specific therapeutic expertise to deliver oncology trials of all sizes across the drug development spectrum.
Mr. Baker said, “Nexus is a first-class organization that has a history of providing excellent service in oncology clinical trials throughout the world. The experience of the Nexus clinical team and their leadership will help the newly enlarged company to expand our services and be a force in getting life-saving oncologic drugs to market more efficiently. Ockham is excited to have Nexus as part of our family as we move forward in our quest to be the number one global oncology and specialty services CRO in the world.”
Ms. Wareing added, “We are absolutely delighted to be part of this new organization. This transaction enables us to realize a long-held ambition of being a global full-service oncology CRO with a larger geographic footprint and a wider and deeper service offering.”